<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The molecular pathophysiology in inflammatory myopathies</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Elsevier BV</publisher>
				<availability status="unknown"><p>Copyright Elsevier BV</p>
				</availability>
				<date type="published" when="2004-04-23">23 april 2004</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
							<email>dalakasm@ninds.nih.gov</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">NINDS</orgName>
								<orgName type="department" key="dep2">Diseases and Stroke</orgName>
								<orgName type="institution" key="instit1">Neuromuscular Diseases Section</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<orgName type="institution" key="instit3">NIH</orgName>
								<orgName type="institution" key="instit4">National Institute of Neurological</orgName>
								<address>
									<addrLine>10 Center Drive, MSC 1382, Building 10, Room 4N248</addrLine>
									<postCode>20892-1382</postCode>
									<settlement>Bethesda</settlement>
									<region>MD</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The molecular pathophysiology in inflammatory myopathies</title>
					</analytic>
					<monogr>
						<title level="j" type="main">La Revue de Médecine Interne</title>
						<title level="j" type="abbrev">La Revue de Médecine Interne</title>
						<idno type="ISSN">0248-8663</idno>
						<imprint>
							<publisher>Elsevier BV</publisher>
							<biblScope unit="volume">25</biblScope>
							<biblScope unit="page" from="S14" to="S16"/>
							<date type="published" when="2004-04-23">23 april 2004</date>
						</imprint>
					</monogr>
					<idno type="MD5">6B3A127DDA891D87FBAF168F42AD8840</idno>
					<idno type="DOI">10.1016/j.revmed.2004.04.007</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Clinical features</head><p>On the basis of unique clinical, immunopathologic, demographic, histologic and prognostic criteria, along with different response to therapies, the inflammatory myopathies comprise of three major subsets: Polymyositis (PM), Dermatomyositis (DM) and Inclusion-Body Myositis (IBM) <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. The diseases are clinically important because they represent the largest group of acquired and potentially treatable myopathies both in children and adults.</p><p>All three forms have in common a myopathy characterized by proximal and often symmetric muscle weakness that develops relatively slowly (weeks to months) and occasionally insidiously, as in IBM, but rarely acutely. DM is a distinct clinical entity identified by a characteristic heliotrope rash on the upper eyelids, face or upper truck that accompanies, or more often precedes, the evolving muscle weakness <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. PM mimics many other myopathies and it is a diagnosis of exclusion. It is best defined as an inflammatory myopathy that develops subacutely, over weeks to months, progresses steadily and occurs in adults who do not have a rash, involvement of the extraocular and facial muscles (mild facial weakness is seen in IBM but not in PM), family history of a neuromuscular disease, history of exposure to myotoxic drugs or toxins, endocrinopathy, neurogenic disease, dystrophy, biochemical muscle disorder or inclusion-body myositis, as determined by muscle enzyme histochemistry and biochemistry <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. It is now increasingly recognized that PM, occurring in isolation, is a rare and rather overdiagnosed disorder; it is more often seen in association with systemic autoimmune or connective tissue diseases, or with known viral or bacterial infection <ref type="bibr" target="#b1">[2]</ref>. IBM is the most common acquired myopathy in men above 50 years old. Although it is commonly suspected when a patient with presumed PM does not respond to therapy, involvement of distal muscles, especially foot extensors and deep finger flexors, in almost all the cases, may be a clue to the early clinical diagnosis <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. Dysphagia is common, occurring in up to 60% of the patients, especially late in the disease <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</p><p>The clinically suspected diagnosis of PM, DM, or IBM is established or confirmed by elevated activity of the musclederived serum enzymes, electromyographic findings, and muscle biopsy <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>. Muscle biopsy is the definitive test for establishing the diagnosis of inflammatory myopathy and for excluding other neuromuscular diseases. Inflammation is the histologic hallmark for these diseases; however, additional features are characteristic of each subtype <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>. In PM and IBM the inflammation is primary, a term used to indicate that T cell infiltrates, located primarily within the muscle fascicles (endomysially), surround individual, healthy muscle fibers that eventually invade resulting in phagocytosis and necrosis <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>. The MHC-1 expression is ubiquitously expressed on the sarcolemma even in fibers not invaded by CD8+ cells <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>. The CD8/MHC-1 lesion is fundamental for confirming the diagnosis of PM and excluding disorders with secondary, non-specific inflammation, as seen in various toxic, metabolic or dystrophic myopathies <ref type="bibr" target="#b1">[2]</ref>. In IBM, in addition to the inflammation, there are granular deposits distributed around the edge of slit-like vacuoles (rimmed vacuoles) along with tiny congophilic amyloid deposits within or next to the vacuoles, best visualized by Texas-red fluorescent optics <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>. Search for the CD8/MHC-1 expression should be in the diagnostic criteria of PM to avoid misdiagnoses, as recently emphasized <ref type="bibr" target="#b1">[2]</ref>. In DM the endomysial inflammation is predominantly perivascular or in the interfascicular septae and around, rather than within, the muscle fascicles. The muscles fibers undergo necrosis, degeneration, and phagocytosis, often in groups involving a portion of a muscle fasciculus in a wedge-like shape or at the periphery of the fascicle, due to microinfarcts within the muscle <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> resulting in perifascicular atrophy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Molecular immunopathogenesis</head><p>In DM, the endomysial infiltrates have a higher than normal percentage of B cells, a higher ratio of CD4+ cells (helper cells) to CD8+ cells (suppressor-cytotoxic T cells), proximity of CD4+ cells to B cells and macrophages, and a relative absence of lymphocytic invasion of nonnecrotic muscle fibers, all of which suggest a mechanism mediated primarily by humoral processes <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>. The immune process is directed against microvascular antigens and is mediated by the complement C5b-9 membranolytic attack complex, resulting in necrosis of the endothelial cells, reduced numbers of endomysial capillaries, ischemia, muscle-fiber destruction often resembling microinfarcts, and inflammation. The remaining capillaries have dilated lumen in an effort to compensate for the ischemic process.</p><p>In PM and IBM there is evidence of an antigen-directed cytotoxicity mediated by CD8+ cytotoxic T cells <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>. This conclusion is supported by the presence of CD8+ cells which, along with macrophages, initially surround and eventually invade and destroy healthy, nonnecrotic, muscle fibers that aberrantly express class I MHC molecules. MHC-I expression, absent from the sarcolemma of normal muscle fibers, is probably induced by cytokines secreted by activated T cells and macrophages. The CD8/MHC-I complex is characteristic for PM and IBM; its detection has now become necessary to confirm the histological diagnosis of PM. The cytotoxic autoinvasive CD8+ T cells contain perforin and granzyme granules directed towards the surface of the muscle fibers; these granules are capable of inducing necrosis of the muscle cell.</p><p>In PM and IBM, certain infiltrating endomysial CD8+ T cells of specific T cell Receptor (TCR) families are clonally expanded and their CDR3 region, the antigen-binding region of the TCR, has conserved aminoacid sequences, suggesting an antigen-driven T cell response <ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b8">[8]</ref><ref type="bibr" target="#b9">[9]</ref>. In contrast, the non-invasive, bystander T cells are clonally diverse. Sequential muscle biopsy specimens has further shown a persistent clonal restriction of the same TCR families suggesting that the endomysial T cells appear driven continuously by the same, heretofore unknown, antigen(s) <ref type="bibr" target="#b10">[10,</ref><ref type="bibr" target="#b11">11]</ref>. The B7family of costimulatory molecules, BB-1 and ICOS (Inducible Costimulator), and their ligands CD28/CTLA-4 and LICOS are also upregulated on the muscle fibers and the autoinvasive CD8+ T cells <ref type="bibr" target="#b11">[11,</ref><ref type="bibr" target="#b12">12]</ref>. In addition, T cellderived cytokines (IL 2,4,5 ,IFN-c), macrophage-derived cytokines (IL 1 , IL 6 , TNFa), chemokines MCP-1 (CCL2), Mig (CXCL9) and their receptors, matrix metalloproteinsases (MMP-2 and MMP-9), adhesion molecules on leukocytes (L-selectin and integrins LFA-1, VLA-4) and their respective ligands on endothelial cells (GlyCAM-1, ICAM-1, VCAM-1), are upregulated in patients with PM and IBM and facilitate the adhesion and transmigration of activated T cells through the endothelial cell wall <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b13">13]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Treatment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Present therapies</head><p>Because the specific target antigens in DM, PM and IBM are unknown, the immunosuppressive therapies are not selectively targeting the autoreactive T cells or the complement-mediated process on the intramuscular blood vessels. Instead, they are inducing a non-selective immunosuppression or immunomodulation. Agents used in the treatment of PM and DM include: Corticosteroids, Azathioprine, Methotrexate, Cyclophosphamide, Chlorambucil, Cyclosporine, Mycophenolate Mofetil, and Intravenous Immunoglobulin (IVIg) which is the only drug tested in control trials <ref type="bibr" target="#b14">[14,</ref><ref type="bibr" target="#b15">15]</ref>. IVIg was first shown to be effective in uncontrolled studies <ref type="bibr" target="#b15">[15]</ref>. A first double-blind study conducted, demonstrated that IVIg is effective in patients with refractory DM <ref type="bibr" target="#b16">[16]</ref>. Not only the strength improves but the underlying immunopathology resolves. A controlled double-blind study for PM has never been completed <ref type="bibr" target="#b17">[17]</ref>. IVIg has also exerted some benefit, although not statistically significant, in up to 30% of patients with IBM in a controlled double-blind study <ref type="bibr" target="#b18">[18]</ref>. Although the improvement was not dramatic, it made a difference to these patients' life styles especially on dysphagia.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Future immunotherapies</head><p>Progress in molecular immunology promises a more target-oriented immunotherapy in the years to come targeting: (a) the signal transduction in T lymphocytes, using monoclonal antibodies against CD52, CD3, CD45, ICAM, LFA3 or IL2R; (b) immunomodulating cytokines, such as TNF-a or interferons; and (c) adhesion molecules and receptors, such as MMP-2 and MMP-9, integrins and their receptors <ref type="bibr" target="#b14">[14]</ref>.</p></div>		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Polymyositis, dermatomyositis and inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="1487" to="1498" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="971" to="982" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Muscle biopsy findings in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin N Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="779" to="798" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The immunobiology of muscle</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Today</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="269" to="274" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies III. Immunoelectron microscopy aspects of cellmediated muscle fiber injury</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="112" to="125" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Nishio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Miyasaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kohsaka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="4051" to="4058" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Dalakas / La revue de médecine interne</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2004">2004</date>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="S14" to="S16" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients</title>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cherin</forename><forename type="middle">P</forename><surname>Maisonobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="3521" to="3529" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR and CDR3 spectratype analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hofbauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wiesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Babbe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="4090" to="4095" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Molecular immunology and genetics of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1509" to="1512" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Understanding the immunopathogenesis of inclusion body myositis: present and future prospects</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="948" to="958" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Murata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="453" to="460" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Muscle fibers and cultured muscle cells express the B7.1/2 related costimulatory molecule ICOSL: implications for the pathogenesis of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitsdoerffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="1026" to="1035" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Civate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle and Nerve</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="659" to="682" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Therapeutic strategies in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Neurol</title>
		<imprint>
			<biblScope unit="page" from="199" to="206" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Efficacy of intravenous immunoglobulin therapy in chronic refractory polymyositis and dermatomyositis. An open study with 20 adult patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wechsler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="162" to="168" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Illa</forename><forename type="middle">I</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Soueidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Otero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="page" from="1993" to="2000" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="537" to="545" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Sivalcumar K. Treatment of inclusion body myositis with IVIg: A doubleblind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sonies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sekul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="712" to="716" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
